A new drug called Bepirovirsen holds the promise of new advances in the treatment of hepatitis B. The drug, a promising antisense oligonucleotide, is being developed by GSK (GlaxoSmithKline). Phase III data published in May 2026 showed significant functional cure rates (19% in the overall population, 26% in patients with lower viral activity), which could make Bepirovirsen a potential game-changer.<\/p>\n
Bepirovirsen is a \u2018triple-action\u2019 drug that destroys viral RNA, reduces the production of hepatitis B surface antigens (HBsAg) and stimulates the immune system to control the virus.
\nThe goal is a functional cure. This occurs when the HBsAg antigen is no longer detectable in the blood at least 24 weeks after the end of treatment, without further medication. <\/p>\n
In the B-Well Phase III trials, high rates of functional cure were observed compared to 0% with standard therapies.
\nIn an exploratory analysis, 49% of those treated achieved an HBsAg level of \u2264 100 IU\/mL one year after the end of treatment. <\/p>\n
The US regulatory authority, the FDA, has granted Bepirovirsen Breakthrough Therapy Designation and initiated a Priority Review. <\/p>\n","protected":false},"excerpt":{"rendered":"
A new drug called Bepirovirsen holds the promise of new advances in the treatment of hepatitis B. The drug, a promising antisense oligonucleotide, is being developed by GSK (GlaxoSmithKline). Phase III data published in May 2026 showed significant functional cure rates (19% in the overall population, 26% in patients with lower viral activity), which could\u2026 Read More »<\/a><\/span><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-5004","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/hepc.ch\/en\/wp-json\/wp\/v2\/posts\/5004","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hepc.ch\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hepc.ch\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hepc.ch\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/hepc.ch\/en\/wp-json\/wp\/v2\/comments?post=5004"}],"version-history":[{"count":1,"href":"https:\/\/hepc.ch\/en\/wp-json\/wp\/v2\/posts\/5004\/revisions"}],"predecessor-version":[{"id":5007,"href":"https:\/\/hepc.ch\/en\/wp-json\/wp\/v2\/posts\/5004\/revisions\/5007"}],"wp:attachment":[{"href":"https:\/\/hepc.ch\/en\/wp-json\/wp\/v2\/media?parent=5004"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hepc.ch\/en\/wp-json\/wp\/v2\/categories?post=5004"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hepc.ch\/en\/wp-json\/wp\/v2\/tags?post=5004"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}